Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function

被引：13

作者：

Iyer, SS

Morgan, JC

Sethi, KD

机构：

[1] Med Coll Georgia, Movement Disorders Program, Dept Neurol, Augusta, GA 30912 USA

[2] Dept Vet Affairs Med Ctr, Augusta, GA USA

来源：

NEUROLOGY | 2005年 / 65卷 / 09期

关键词：

D O I：

10.1212/01.wnl.0000183286.92632.71

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：1507 / 1507

页数：1

共 7 条

[1]

Blindauer K, 2003, ARCH NEUROL-CHICAGO, V60, P1721

[2] ABSORPTION OF LEVODOPA AFTER RECTAL ADMINISTRATION [J].

EISLER, T ;

ENG, N ;

PLOTKIN, C ;

CALNE, DB .

NEUROLOGY, 1981, 31 (02) :215-217

[3] Orally fast disintegrating tablets: Developments, technologies, taste-masking and clinical studies [J].

Fu, YR ;

Yang, SC ;

Jeong, SH ;

Kimura, S ;

Park, K .

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2004, 21 (06) :433-475

[4] Other formulations and future considerations for apomorphine for subcutaneous injection therapy [J].

Koller, W ;

Stacy, M .

NEUROLOGY, 2004, 62 (06) :S22-S26

[5] A multicenter, open-label, sequential study comparing preferences for Carbidopa-Levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease [J].

Nausieda, PA ;

Pfeiffer, RF ;

Tagliati, M ;

Kastenholz, KV ;

DeRoche, C ;

Slevin, JT .

CLINICAL THERAPEUTICS, 2005, 27 (01) :58-63

[6] Gastrointestinal dysfunction in Parkinson's disease [J].

Pfeiffer, RF .

LANCET NEUROLOGY, 2003, 2 (02) :107-116

[7] Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations:: A 3-month, randomized, placebo-controlled study [J].

Waters, CH ;

Sethi, KD ;

Hauser, RA ;

Molho, E ;

Bertoni, JA .

MOVEMENT DISORDERS, 2004, 19 (04) :426-432

← 1 →